The forecast for cardiovascular system medicine sales in the UK from 2024 to 2028 shows a gradual decline, starting from an estimated $1.55 billion in 2024 and decreasing to $1.45 billion by 2028. This represents a compound annual growth rate (CAGR) of approximately -1.62%, signaling a modest contraction in market value. The data provided does not include previous year's actual values to calculate exact year-on-year variations.

Future trends to watch for:

Potential impact of government healthcare policies on drug pricing.
Emergence of new treatments or technology affecting cardiovascular therapies.
Changes in population demographics increasing demand for cardiovascular medicines.
Brexit's long-term effects on the pharmaceutical supply chain and market dynamics.